Published April 19, 2016 | Version v1
Journal article Open

Urine proteomics in the diagnosis of stable angina

  • 1. BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK
  • 2. mosaiques diagnostics GmbH, Rotenburger Str. 20, 30659, Hannover, Germany

Description

Background: We have previously described a panel of 238 urinary polypeptides specific for established severe coronary artery disease (CAD). Here we studied this polypeptide panel in patients with a wider range of CAD severity.

Methods: We recruited 60 patients who underwent elective coronary angiography for investigation of stable angina. Patients were selected for either having angiographic evidence of CAD or not (NCA) following coronary angiography (n = 30/30; age, 55 ± 6 vs. 56 ± 7 years, P = 0.539) to cover the extremes of the CAD spectrum. A further 66 patients with severe CAD (age, 64 ± 9 years) prior to surgical coronary revascularization were added for correlation studies. The Gensini score was calculated from coronary angiograms as a measure of CAD severity. Urinary proteomic analyses were performed using capillary electrophoresis coupled online to micro time-of-flight mass spectrometry. The urinary polypeptide pattern was classified using a predefined algorithm and resulting in the CAD238 score, which expresses the pattern quantitatively.

Results: In the whole cohort of patients with CAD (Gensini score 60 [40; 98]) we found a close correlation between Gensini scores and CAD238 (ρ = 0.465, P < 0.001). After adjustment for age (β = 0.144; P = 0.135) the CAD238 score remained a significant predictor of the Gensini score (β =0.418; P < 0.001). In those with less severe CAD (Gensini score 40 [25; 61]), however, we could not detect a difference in CAD238 compared to patients with NCA (−0.487 ± 0.341 vs. −0.612 ± 0.269, P = 0.119).

Conclusions: In conclusion the urinary polypeptide CAD238 score is associated with CAD burden and has potential as a new cardiovascular biomarker.

Files

12872_2016_Article_246.pdf

Files (1.8 MB)

Name Size Download all
md5:3655da49b25d351e9e7e925b874d8024
1.2 MB Download
md5:0fa704a86d427440d8dde8ffdcd59033
570.4 kB Preview Download
md5:1622f01eb6f16e5f7e0325ba5dcf83b5
22.9 kB Download

Additional details

Funding

European Commission
HOMAGE - Heart OMics in AGEing 305507
European Commission
EU-MASCARA - Markers for Sub-Clinical Cardiovascular Risk Assessemnt 278249